KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Debt (2018 - 2025)

Historic Total Debt for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $31.4 billion.

  • Takeda Pharmaceutical's Total Debt fell 975.46% to $31.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $31.4 billion, marking a year-over-year decrease of 975.46%. This contributed to the annual value of $29.7 billion for FY2025, which is 1170.76% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Total Debt stood at $31.4 billion for Q4 2025, which was down 975.46% from $33.2 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Total Debt ranged from a high of $45.9 billion in Q1 2021 and a low of $29.6 billion during Q1 2025
  • In the last 5 years, Takeda Pharmaceutical's Total Debt had a median value of $34.3 billion in 2022 and averaged $35.6 billion.
  • Per our database at Business Quant, Takeda Pharmaceutical's Total Debt crashed by 2425.72% in 2022 and then skyrocketed by 647.48% in 2024.
  • Takeda Pharmaceutical's Total Debt (Quarter) stood at $41.3 billion in 2021, then decreased by 24.26% to $31.3 billion in 2022, then increased by 4.61% to $32.7 billion in 2023, then grew by 6.47% to $34.8 billion in 2024, then fell by 9.75% to $31.4 billion in 2025.
  • Its last three reported values are $31.4 billion in Q4 2025, $33.2 billion for Q3 2025, and $32.3 billion during Q2 2025.